首页> 外文OA文献 >Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation▿
【2h】

Differential Regulation of Cyclin-Dependent Kinase 4 (CDK4) and CDK6, Evidence that CDK4 Might Not Be Activated by CDK7, and Design of a CDK6 Activating Mutation▿

机译:细胞周期蛋白依赖性激酶4(CDK4)和CDK6的差异调节,CDK7可能不会激活CDK4的证据以及CDK6激活突变的设计▿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The homologous cyclin-dependent kinases (CDK) CDK4 and CDK6 integrate mitogenic and oncogenic signaling cascades with the cell cycle. Their activation requires binding to a D-type cyclin and then T-loop phosphorylation at T172 and T177 (respectively) by the only CDK-activating kinase identified in animal cells, cyclin H-CDK7. At odds with the existing data showing the constitutive activity of CDK7, we have recently identified the T172 phosphorylation of cyclin D-bound CDK4 as a crucial cell cycle regulatory target. Here we show that T172 phosphorylation of CDK4 is conditioned by its unique proline 173 residue. In contrast to CDK4, CDK6 does not contain such a proline and, unexpectedly, remained poorly phosphorylated and active in a variety of cells. Mutations of proline 173 did not adversely affect CDK4 activation by CDK7, but in cells they abolished CDK4 T172 phosphorylation and activity. Conversely, substituting a proline for the corresponding residue of CDK6 enforced its complete, apparently cyclin-independent T177 phosphorylation and dramatically increased its activity. These results lead us to propose that CDK4 might not be phosphorylated by CDK7 in intact cells but is more likely phosphorylated by another, presumably proline-directed kinase(s). Moreover, they provide a new model of a potentially oncogenic activating mutation of a CDK.
机译:同源细胞周期蛋白依赖性激酶(CDK)CDK4和CDK6将有丝分裂和致癌信号传导级联与细胞周期整合在一起。它们的激活需要与D型细胞周期蛋白结合,然后通过在动物细胞中鉴定出的唯一CDK激活激酶,即细胞周期蛋白H-CDK7,分别在T172和T177进行T环磷酸化。与现有数据显示CDK7的组成活性不一致,我们最近发现细胞周期蛋白D结合CDK4的T172磷酸化是关键的细胞周期调控靶标。在这里,我们显示CDK4的T172磷酸化受到其独特的脯氨酸173残基的调节。与CDK4相比,CDK6不包含这种脯氨酸,并且出乎意料的是,在各种细胞中磷酸化程度很低,并且活性很弱。脯氨酸173的突变不会对CDK7激活CDK4产生不利影响,但是在细胞中它们消除了CDK4 T172的磷酸化和活性。相反,用脯氨酸代替CDK6的相应残基会增强其完整的,明显与细胞周期蛋白无关的T177磷酸化作用,并显着提高其活性。这些结果使我们提出,在完整细胞中CDK4可能不会被CDK7磷酸化,而更有可能被另一种可能是脯氨酸定向的激酶磷酸化。此外,它们提供了CDK潜在致癌激活突变的新模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号